- Home
- PX vs CVAC Comparison
PX vs CVAC Comparison
Compare PX & CVAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PX
- CVAC
- Stock Information
- Founded
- PX 1992
- CVAC 2000
- Country
- PX United States
- CVAC Germany
- Employees
- PX N/A
- CVAC N/A
- Industry
- PX Investment Managers
- CVAC Biotechnology: Pharmaceutical Preparations
- Sector
- PX Finance
- CVAC Health Care
- Exchange
- PX Nasdaq
- CVAC Nasdaq
- Market Cap
- PX 1.4B
- CVAC 1.2B
- IPO Year
- PX 2021
- CVAC 2020
- Fundamental
- Price
- PX $12.15
- CVAC $5.34
- Analyst Decision
- PX Buy
- CVAC Hold
- Analyst Count
- PX 7
- CVAC 3
- Target Price
- PX $14.64
- CVAC $6.83
- AVG Volume (30 Days)
- PX 386.4K
- CVAC 482.2K
- Earning Date
- PX 11-06-2025
- CVAC 11-11-2025
- Dividend Yield
- PX 1.24%
- CVAC N/A
- EPS Growth
- PX 640.39
- CVAC N/A
- EPS
- PX 0.13
- CVAC 1.01
- Revenue
- PX $299,628,000.00
- CVAC $599,540,810.00
- Revenue This Year
- PX $4.33
- CVAC N/A
- Revenue Next Year
- PX $17.44
- CVAC $24.04
- P/E Ratio
- PX $94.71
- CVAC $5.30
- Revenue Growth
- PX 15.60
- CVAC 675.15
- 52 Week Low
- PX $8.85
- CVAC $2.37
- 52 Week High
- PX $14.28
- CVAC $5.72
- Technical
- Relative Strength Index (RSI)
- PX 48.95
- CVAC 42.37
- Support Level
- PX $11.92
- CVAC $5.33
- Resistance Level
- PX $12.55
- CVAC $5.41
- Average True Range (ATR)
- PX 0.30
- CVAC 0.04
- MACD
- PX -0.05
- CVAC -0.01
- Stochastic Oscillator
- PX 35.16
- CVAC 15.38
About PX P10 Inc.
P10 Inc is a player in the alternative asset management sector, specializing in multi-asset class private market solutions. It offers a range of investment solutions, including specialized funds, separate accounts, secondary investments, direct investments, and co-investments across various asset classes and geographies. These solutions cater to diverse investor needs within the private markets, aiming to deliver superior risk-adjusted returns. With a focus on middle and lower-middle markets, the company's portfolio includes Private Equity, Venture Capital, Impact Investing, and Private Credit. Its Revenue primarily comes from recurring management and advisory fees earned on committed capital, typically locked up for ten to fifteen years.
About CVAC CureVac N.V.
CureVac NV is a biopharmaceutical company headquartered in Germany that is developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA) that has the potential to improve the lives of people. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and COVID-19 vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.